

Product datasheet for **TL314748**

AP3D1 Human shRNA Plasmid Kit (Locus ID 8943)

Product data:

| | |
|---------------------------|--|
| Product Type: | shRNA Plasmids |
| Product Name: | AP3D1 Human shRNA Plasmid Kit (Locus ID 8943) |
| Locus ID: | 8943 |
| Synonyms: | ADTD; hBLVR |
| Vector: | pGFP-C-shLenti (TR30023) |
| E. coli Selection: | Chloramphenicol (34 ug/ml) |
| Mammalian Cell Selection: | Puromycin |
| Format: | Lentiviral plasmids |
| Components: | AP3D1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 8943). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
| RefSeq: | NM_001077523 , NM_001261826 , NM_003938 , NM_003938.1 , NM_003938.2 , NM_003938.3 , NM_003938.4 , NM_003938.5 , NM_003938.6 , NM_001261826.1 , NM_001077523.1 , BC005142 , BC010065 , BC022837 , BM982261 , NM_001261826.3 , NM_003938.8 |
| UniProt ID: | Q14617 |
| Summary: | The protein encoded by this gene is a subunit of the AP3 adaptor-like complex, which is not clathrin-associated, but is associated with the golgi region, as well as more peripheral structures. The AP-3 complex facilitates the budding of vesicles from the golgi membrane, and may be directly involved in trafficking to lysosomes. This subunit is implicated in intracellular biogenesis and trafficking of pigment granules, and possibly platelet dense granules and neurotransmitter vesicles. Defects in this gene are a cause of a new type of Hermansky-Pudlak syndrome. [provided by RefSeq, Feb 2017] |
| shRNA Design: | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service . |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).